Glenmark Pharmaceuticals informed it has entered into an agreement with Boston‐based biopharmaceutical firm APC Therapeutics to in-license the latter’s novel immune-oncology molecule. The financial details of the details were not disclosed.
However, under the terms of the agreement, Glenmark will in-license the product from APC Therapeutics, and manage all clinical development including regulatory filings and commercialisation worldwide. Glenmark will have exclusive rights on the drug.
APC Therapeutics will receive development milestones and sales royalty payments. The compound has the potential to be used as a monotherapy or in combination with approved therapies to address unmet needs in cancer treatment.
“This asset adds to our robust biologics pipeline of targeted IO therapies,” said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals. “The mechanism of action of Antigen Presenting Cell (APC) biology is very intriguing and has the potential to be transformative in cancer treatment by triggering powerful immunologic responses to tumors that may lead to deeper and more durable responses to treatment.”
“Glenmark is an ideal partner to advance such an important scientific breakthrough treatment to patients with cancer,” said Vinod Patel and Venkateshwar Reddy, the co‐founders of APC Therapeutics. “This partnership is strategically significant for APC Therapeutics as it validates and advances our commitment to bring the right immunotherapies to the right patient populations,” the cofounders added.
The global oncology market is growing exponentially and projected to exceed $150 billion by 2020, according to figures from IMS Health. Driving this growth is the transition from short‐term cytotoxic treatments towards precision medicines, most notably immune-oncology agents providing substantial increase in long‐term survival. Because of these improvements, immune-oncology is one of the most promising and fastest growing areas of cancer treatment and research.
Glenmark is one among very few companies with a drug discovery programme. The company has a diverse pipeline with several compounds in various stages of clinical development, primarily focused in the areas of oncology, respiratory, and dermatology and includes three bispecific monoclonal antibodies (bsABs) and an antibody‐based agonist targeting OX40R. The immuno‐oncology pipeline currently includes four candidates being studied in a wide‐range of tumor types.